Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 54 out of 100. How common it is

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Recent epidemiological studies show a strong reduction in the incidence of Alzheimer's disease in patients treated with cholesterol-lowering statins. Moreover, elevated Abeta42 levels and the varepsilon4 allele of the lipid-carrier apolipoprotein E are regarded as risk factors for sporadic and familial Alzheimer's disease. Here we demonstrate that the widely used cholesterol-lowering drugs simvastatin and lovastatin reduce intracellular and extracellular levels of Abeta42 and Abeta40 peptides in primary cultures of hippocampal neurons and mixed cortical neurons. Likewise, guinea pigs treated with high doses of simvastatin showed a strong and reversible reduction of cerebral Abeta42 and Abeta40 levels in the cerebrospinal fluid and brain homogenate. These results suggest that lipids are playing an important role in the development of Alzheimer's disease. Lowered levels of Abeta42 may provide the mechanism for the observed reduced incidence of dementia in statin-treated patients and may open up avenues for therapeutic interventions.

What this study adds

Evidence grade: Low

The authors propose that lower Abeta42 "may provide the mechanism" for the reduced dementia rates reported in statin users by earlier population studies, but this paper studied no people and measured no memory or dementia outcomes. These are laboratory and animal results that the authors say "may open up avenues for therapeutic interventions"; they do not show that statins prevent or treat Alzheimer's.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Fassbender, K., Simons, M., Bergmann, C., Stroick, M., Lutjohann, D., Keller, P., et al. (2001). Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proceedings of the National Academy of Sciences of the United States of America. https://doi.org/10.1073/pnas.081620098

Vancouver

Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, et al. Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proceedings of the National Academy of Sciences of the United States of America. 2001. doi:10.1073/pnas.081620098. PMID: 11296263.

BibTeX

@article{fassbender2001-11296263,
  author  = {Fassbender, K. and Simons, M. and Bergmann, C. and Stroick, M. and Lutjohann, D. and Keller, P. and Runz, H. and Kuhl, S. and others},
  title   = {{Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo}},
  journal = {Proceedings of the National Academy of Sciences of the United States of America},
  year    = {2001},
  doi     = {10.1073/pnas.081620098},
  pmid    = {11296263},
  url     = {https://doi.org/10.1073/pnas.081620098}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

In nerve cells grown in the lab, the cholesterol-lowering drugs simvastatin and lovastatin lowered levels of the amyloid-beta peptides Abeta42 and Abeta40; in guinea pigs given high doses of simvastatin, these levels fell in cerebrospinal fluid and brain and the fall was reversible. The authors propose that lower Abeta42 "may provide the mechanism" for the reduced dementia rates reported in statin users by earlier population studies, but this paper studied no people and measured no memory or dementia outcomes. These are laboratory and animal results that the authors say "may open up avenues for therapeutic interventions"; they do not show that statins prevent or treat Alzheimer's.

Study details

How this study scored 54/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 4 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 7 of 7; Citations per year 4 of 5; Impact for its field and year 6 of 6; Cited by studies here 4 of 6; Still being cited 2 of 4; Senior author's track record 3 of 4; Institution's track record 1 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 54 of 100.54 of 100 points earned46 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Proceedings of the National Academy of Sciences of the United States of America)
Journal's citation record 4 / 4 Proceedings of the National Academy of Sciences: journal h-index 1,167 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2001 — older than 20 years, still counted
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Laboratory or animal study (title names “in vitro”) — scores zero
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 7 / 7 Cited 1,092 times (OpenAlex, 2026-10-10)
Citations per year 4 / 5 40.4 citations a year over 27 year(s) since 2001
Impact for its field and year 6 / 6 Cited 49.7× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 4 / 6 Cited by 43 other studies in this library
Still being cited 2 / 4 Cited 34 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Tobias Hartmann: h-index 69 (OpenAlex, whole career)
Institution's track record 1 / 3 Heidelberg University: institution h-index 1,344 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 6 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 11296263)
Free to read 0 / 2 Behind a paywall — scores zero
Total 54 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

43 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in How common it is from nearby years

Also tagged “trial”

783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on How common it is

See all studies in How common it is →